Cardiovascular Systems, Inc., a medical technology company, develops, makes, and markets devices to treat vascular diseases in the United States. The company has market cap of $880.34 million. The firm offers peripheral arterial disease products, including Diamondback 360 Peripheral Orbital Atherectomy System , Diamondback 360 60cm Peripheral OAS, Diamondback 360 4 French 1.25 Peripheral OAS, Diamondback 360 1.50 Peripheral OAS, Diamondback 360 2.00 Peripheral OAS, and Stealth 360 Peripheral OAS, which are catheter platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives. It currently has negative earnings. It also provides Diamondback 360 Coronary OAS, an atherectomy device for the treatment of calcified coronary arteries.
Masters Capital Management Llc decreased Kite Pharma Inc (Call) (KITE) stake by 50% reported in 2017Q2 SEC filing. Masters Capital Management Llc sold 100,000 shares as Kite Pharma Inc (Call) (KITE)’s stock rose 29.36%. The Masters Capital Management Llc holds 100,000 shares with $10.37 million value, down from 200,000 last quarter. Kite Pharma Inc (Call) now has $10.31 billion valuation. It closed at $179.79 lastly. It is down 55.47% since November 30, 2016 and is uptrending. It has outperformed by 38.77% the S&P500.
Analysts await Cardiovascular Systems, Inc. (NASDAQ:CSII) to report earnings on January, 24. They expect $-0.04 earnings per share, down 233.33% or $0.07 from last year’s $0.03 per share. After $-0.06 actual earnings per share reported by Cardiovascular Systems, Inc. for the previous quarter, Wall Street now forecasts -33.33% EPS growth.
Perkins Capital Management Inc holds 2.45% of its portfolio in Cardiovascular Systems, Inc. for 68,550 shares. Hussman Strategic Advisors Inc. owns 200,000 shares or 1.43% of their US portfolio. Moreover, Timpani Capital Management Llc has 1.39% invested in the company for 116,397 shares. The Massachusetts-based Ironwood Investment Management Llc has invested 1.36% in the stock. Cortina Asset Management Llc, a Wisconsin-based fund reported 830,867 shares.
The stock decreased 0.35% or $0.09 during the last trading session, reaching $25.8. About 16,788 shares traded. Cardiovascular Systems, Inc. (CSII) has risen 113.78% since November 30, 2016 and is uptrending. It has outperformed by 97.08% the S&P500.
Masters Capital Management Llc increased Deutsche Bank Ag (Call) (NYSE:DB) stake by 1.91 million shares to 4.91 million valued at $87.40 million in 2017Q2. It also upped Intel Corp (Call) (NASDAQ:INTC) stake by 1.00 million shares and now owns 2.00 million shares. Neophotonics Corp (NYSE:NPTN) was raised too.
Among 20 analysts covering Kite Pharma (NASDAQ:KITE), 10 have Buy rating, 0 Sell and 10 Hold. Therefore 50% are positive. Kite Pharma had 53 analyst reports since August 4, 2015 according to SRatingsIntel. The rating was upgraded by Wedbush on Tuesday, August 29 to “Neutral”. Standpoint Research downgraded the stock to “Hold” rating in Friday, November 13 report. On Wednesday, June 7 the stock rating was maintained by Cowen & Co with “Buy”. As per Monday, October 23, the company rating was maintained by Canaccord Genuity. The firm earned “Hold” rating on Tuesday, August 29 by Canaccord Genuity. Cowen & Co maintained the stock with “Buy” rating in Monday, June 26 report. RBC Capital Markets initiated it with “Outperform” rating and $85 target in Tuesday, February 2 report. The stock has “Buy” rating by TH Capital on Wednesday, January 4. The firm earned “Mkt Perform” rating on Friday, November 13 by FBR Capital. The firm has “Hold” rating given on Monday, August 28 by BTIG Research.
Since June 1, 2017, it had 0 insider buys, and 4 sales for $5.78 million activity. CHAMPSI FARAH sold $1.84 million worth of Kite Pharma, Inc. (NASDAQ:KITE) on Wednesday, June 14. 20,000 shares valued at $1.79M were sold by Ruchefsky Steven B on Wednesday, June 14. $885,491 worth of Kite Pharma, Inc. (NASDAQ:KITE) was sold by BUTITTA CYNTHIA M. Shares for $173,880 were sold by Kim Helen Susan. DOUMANI ROY sold $1.27M worth of Kite Pharma, Inc. (NASDAQ:KITE) on Wednesday, June 7.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.